The main objective of this study is to determine the mechanism by which NK and T cells activated with cytokines undergo apoptosis when they encounter activating ligands on target cells. We observed that human primary NK and T cells that were stimulated in vitro with the cytokines IL-2 and IL-15 showed extensive potential to undergo apoptosis when their activation receptors were cross linked. In order to study this activation induced cell death in NK cells further, we drew incite from our earlier microarray study. Our microarray data on genes that are modulated upon stimulation of human NK cells in culture with IL-2 showed that the anti-apoptotic molecule, TOSO was down regulated in cells cultured with IL-2 by 5 fold. TOSO, also called as Fas Apoptotic Inhibitory Molecule 3 (FAIM3), is a member of immunoglobulin gene superfamily and it inhibits Fas mediated apoptosis. TOSO is expressed mainly by lymphocytes. However, the role of TOSO in the physiological context of NK cell activation and their function is not well known. This prompted us to look into the role of TOSO in activation induced cell death in NK cells, as well as in T and B cells. We quantitated the relative levels of TOSO expression using real time PCR assays and by cell surface staining using a Mab. We found Toso expression correlated with resistance to Fas mediated cell death and conversely, the down-regulation of TOSO expression correlated with susceptibility to Fas- mediated activaton induced cell death (AICD). As expected, we found that human NK cells when stimulated with IL-2 expressed high levels of the Fas death receptor . We verified that Jurkat T cells transfected with TOSO change from AICD susceptible to being resistant. We have recently shown that TOSO over expression can also protect primary human NK cells from AICD. We are also planning to establish a cell line model for stable expression of TOSO. We have also generated TOSO transgenic mice and obtained TOSO knockout mice for these studies. We have a manuscript in prepartion.

Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2009
Total Cost
$440,967
Indirect Cost
City
State
Country
Zip Code
Gil-Krzewska, Aleksandra; Saeed, Mezida B; Oszmiana, Anna et al. (2018) An actin cytoskeletal barrier inhibits lytic granule release from natural killer cells in patients with Chediak-Higashi syndrome. J Allergy Clin Immunol 142:914-927.e6
Chiang, Samuel C C; Wood, Stephanie M; Tesi, Bianca et al. (2017) Differences in Granule Morphology yet Equally Impaired Exocytosis among Cytotoxic T Cells and NK Cells from Chediak-Higashi Syndrome Patients. Front Immunol 8:426
Voss, Oliver H; Murakami, Yousuke; Pena, Mirna Y et al. (2016) Lipopolysaccharide-Induced CD300b Receptor Binding to Toll-like Receptor 4 Alters Signaling to Drive Cytokine Responses that Enhance Septic Shock. Immunity 44:1365-78
Gil-Krzewska, Aleksandra; Wood, Stephanie M; Murakami, Yousuke et al. (2016) Chediak-Higashi syndrome: Lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells. J Allergy Clin Immunol 137:1165-1177
Chen, Zhengshan; Shojaee, Seyedmehdi; Buchner, Maike et al. (2016) Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 534:138
Krzewski, Konrad; Gil-Krzewska, Aleksandra; Nguyen, Victoria et al. (2013) LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 121:4672-83
Murakami, Yousuke; Narayanan, Sriram; Su, Su et al. (2012) Toso, a functional IgM receptor, is regulated by IL-2 in T and NK cells. J Immunol 189:587-97
Krzewski, Konrad; Coligan, John E (2012) Human NK cell lytic granules and regulation of their exocytosis. Front Immunol 3:335